当前位置:首页 >英文主页 >中英对照 > 报告详情

艾昆纬(IQVIA):2025未来已至:AI、ML、NLP及RPA赋能监管流程转型白皮书(英文版)(16页).pdf

上传人: Kell****reet 编号:625009 2025-04-16 16页 1.77MB

下载:

1、White PaperThe Future is Now:The Transformation of Regulatory Processes through AI,ML,NLP,and RPAsMICHELLE GYZEN,Senior Director,Regulatory Innovation&Technology KIRAN CHINNALLA,Director,Regulatory Innovation&Technology ANKIT TYAGI,Director,Regulatory Affairs,Labeling Operation,Regulatory Affairs&Dr

2、ug Development SolutionsTable of contentsIntroduction 1How an intelligence-based regulatory ecosystem would revolutionize 2 regulatory workflowsFour key pillars of automation in a regulatory ecosystem 4The benefits of IQVIA Regulatory Intelligence Assistant(RIA)6AI/ML-enabled regulatory workflows 8A

3、I-assisted regulatory information management systems 10Conclusion 12About IQVIA 12About the authors 13 |1Artificial intelligence(AI)and machine learning(ML)are revolutionizing regulatory activities in the biopharma industry by enabling rapid data analysis for better decision-making,automating routin

4、e tasks to reduce errors and speed up processes,ensuring real-time compliance monitoring to minimize risks,and accelerating drug discovery and development to bring lifesaving drugs to market faster and more economically.By leveraging AI,organizations can streamline their regulatory activities,enhanc

5、e resource optimization,and maintain a competitive edge in a highly regulated environment.IQVIAs mission is to empower regulatory teams with innovative solutions that simplify regulatory activities,enable well-informed decision-making,promote dynamic task management,and institutionalize knowledge.Th

6、e development of automation is a key part of this vision.Our vision encompasses four key components:Regulatory Intelligence Assistant(RIA),orchestrated regulatory workflow manager,AI-assisted regulatory information management and automated content generation.Our AI solutions are designed to revoluti

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要讨论了人工智能(AI)、机器学习(ML)、自然语言处理(NLP)和机器人流程自动化(RPA)如何改变生物制药行业的监管流程。文章指出,这些技术能够实现快速数据分析,提高决策质量,自动化常规任务,减少错误和加快流程,实时合规监控以降低风险,加速药物发现和开发,以更快、更经济的方式将救命药物推向市场。文章提出了一个基于智能的监管生态系统,包括四个关键组件:监管智能助手(RIA)、编排的监管工作流管理器、AI辅助的监管信息管理和自动化内容生成。文章还详细讨论了AI/ML驱动的监管工作流、AI辅助的监管信息管理系统以及自动化内容生成的优势。最后,文章指出,通过AI驱动的编排工作流管理器,可以显著提高监管部门的效率和效果,从而提高合规性,降低风险,优化资源利用。
人工智能如何改变药品监管流程? 自动化技术如何提高药品监管效率? 未来药品监管信息管理系统将如何发展?
客服
商务合作
小程序
服务号
折叠